tion in the highly conserved third extracellular phosphatase domain (p.T299S). The functional relevance of this mutation was verified by in-utero electroporation of a mutant Prg1 construct into neurons of Prg1-knockout embryos, and the subsequent inability of hippocampal neurons to rescue the knockout phenotype on the single cell level. Whole exome sequencing revealed the index patient to additionally harbor a novel heterozygous SCN1A variant (p.N541S) that was inherited from her healthy mother. Only the affected child carried both heterozygous PRG1 and SCN1A mutations. The aggravating effect of Prg1-haploinsufficiency on the epileptic phenotype was verified using the kainate-model of epilepsy. 
INTRODUCTION
Epilepsy is one of the most common neurological disorders in humans, which across North America and Europe affects approximately five people in every 1000 (Banerjee et al, 2009 ).
More than 350 epilepsy-associated genes have been described in the literature. Most of them play an important role in neuronal excitability, cortical development, or synaptic transmission (Noebels, 2017) . The first discovered disease genes to be linked to epilepsy in humans and mice were all subunits of voltage-and ligand-gated ion channels. Mutations in these genes currently constitute approximately one third of nearly 150 monogenic seizure disorders (Noebels, 2017) , affecting either voltage-gated [SCN1A (Escayg et al, 2000) , KCNQ2 (Singh et al, 1998) ] or ligand-gated ion channels [CHRNA4 (Steinlein et al, 1995) , GABRG2 (Baulac et al, 2001; Wallace et al, 2001) ]. The concept of "channelopathy" implies that dysfunction of neuronal ion channels might lead to altered ion currents and destabilization of the membrane potential, potentially leading to increased epileptic network activity.
Mutations in SCN1A mainly cause two epilepsy syndromes, (i) a severe form of epilepsy characterized by fever-associated and afebrile seizures, called "Dravet syndrome" (Depienne et al, 2010) and (ii) a milder dominant familial epilepsy syndrome, called "Genetic Epilepsy with Febrile Seizures Plus" (GEFS+) . The severity of GEFS+ spans a broad phenotypical spectrum ranging from healthy carriers to simple febrile seizures, febrile seizures plus, and sometimes severe forms of epilepsy. On rare occasions SCN1A mutations may cause "Myoclonic-astatic epilepsy", "Infantile spasms" (West syndrome), or Familial Hemiplegic Migraine (FHM) (Dichgans et al, 2005; Oyrer et al, 2018) .
The genetic background, e.g. the interplay of genes jointly contributing to a biologic function such as synthesizing a protein or establishing a neuronal network, may have a profound influence on the penetrance and severity of symptoms of genetic disorders such as epilepsy.
Partially, these phenomena can be modeled in mouse strains with different seizure susceptibilities. As an example, the seizure phenotype of Scn1a dysfunction heavily depends on the genetic background, e.g. the same Scn1a mutation on the 129/SvJ background results in a much milder seizure phenotype than if expressed on the C57BL/6 background (Yu et al, 2006) . Secondly, alleles that cause mild or no phenotypes in isolation may result in more severe epilepsy when combined, as demonstrated in double mutant mice carrying the Scn2a Q54 transgene together with either heterozygous Kcnq2 p. V182M or Kcnq2 del (Szt1) alleles (Kearney et al, 2006) . Even though the importance of various genetic factors is evident in theory, they are mostly unknown.
In Dravet syndrome, a modifying effector has been suggested that may explain the variable expressivity and penetrance of epilepsy in patients with sodium channel mutations (Singh et al, 2009) . Different modifier genes in neural hyperexcitability pathways have been demonstrated in experimental models, e.g. comprising mutations in subunits of voltage-or ligand gated ion channels (Calhoun et al, 2017; Frankel et al, 2014) . Others like the Tau protein play a general role in regulating intrinsic neuronal network hyperexcitability, and deletion of its coding gene suppresses seizures and sudden unexpected death (SUDEP) in different mouse models (Holth et al, 2013; Gheyara et al, 2014) .
Beyond epileptic encephalopathies that are caused by ion channel dysfunction, epilepsy is also caused by mutations in genes involved in pathways regulating synaptic transmission (Appenzeller et al, 2014) , especially through impairment of genes that are involved in pathways of synaptic inhibitory transmission from early development through maturation of adult GABA neurotransmission (Noebels, 2015) .
Here we show that one such pathway is connected with the Plasticity Related Gene 1 (PRG1, syn. PLPPR4 MIM*607813). This cerebral neuron-specific membrane protein is related to lipid-phosphate phosphatases (LPP) and is highly conserved in vertebrates. PRG1 is located at the postsynaptic density of excitatory synapses of glutamatergic cortical neurons.
Postsynaptic PRG1 controls lysophosphatidic acid (LPA) signaling at glutamatergic synapses via presynaptic LPA2 receptors (Trimbuch et al, 2009 ) thereby reducing glutamate release probability and regulating cortical excitability from early postnatal stages (Vogt et al, 2017) .
PRG1 also affects spine density and synaptic plasticity in a cell-autonomous fashion via activation of the protein phosphatase 2A (PP2A)/ITGB1 (Liu et al, 2016, 1) . To test the contribution of PRG1-deficiency to the pathophysiology of epilepsy, we investigated seizure activity in genetically modified mice after kainate application, screened human patients with West syndrome for mutations in PRG1, and functionally validated a mutation by ex vivo electrophysiology recordings in an in-utero electroporation model.
RESULTS

PATIENT STUDIES
Case history
The female patient (Fig. 1A, III: 2) is the second child of non-consanguineous Caucasian parents. She was born at term and developed normally until the age of 6 months, when she exhibited clusters of flexion spasms and developmental regression. The EEG showed hypsarrhythmia suggestive of West syndrome. Cranial MRI and metabolic testing for increased excretion of organic acids or amino acids were normal. Seizures stopped under treatment with sulthiame. The elder brother (III:1) and both parents (II:6, II:7) are healthy. Despite her initial developmental delay, once her seizures were controlled she progressed normally and was able to achieve age-appropriate milestones later in life. Following termination of AED treatment at 2 years of age no further seizures occurred.
Genetic screening revealed a combined heterozygous mutation in the PRG1 and the SCN1A (Fig. 1B, C) . The mutation is located in the third extracellular domain (Fig. 1E) , which is evolutionary conserved in mammals and birds as well as in other LPP protein-family members (Fig. 1D) . The c.896C>G variant was absent in 400 alleles of normal controls from Middle Europe as well as in the individuals of the 1000 genome and 5000 exome projects. It was found once in heterozygous state in one individual from Europe (Non-Finnish) amongst 245,604 alleles from the gnomAD database (http://gnomad.broadinstitute.org | accessed March 2018) (Lek et al, 2016) . The heterozygous p.T299S variant, predicted to be 'disease causing' by MutationTaster2 (Schwarz et al, 2014 ) with a probability of P=0.983, had been inherited from her clinically unaffected father (II:7) letting us assume that the PRG variant might be a modifying factor of a preexisting mutation on another gene. Heterozygous Prg1-mutant mice show increased seizure susceptibility in adulthood.
Having shown that homozygous Prg1 -/-mice had spontaneous seizures during early postnatal development, we investigated the potential of Prg1-haploinsufficiency to modify seizure susceptibility (Fig. 3) . As heterozygous Prg1 +/-mice did not seize spontaneously, we used an established kainate-model in adult animals (McLin & Steward, 2006 (Fig. 3A) .
In addition, Prg1 +/-mice required significantly lower amounts of kainate to progress into their first epileptic seizure than their wildtype littermates (Fig. 3B) . In fact, 23 out of 24
Prg1
+/-mice and all (14 out of 14) Prg1 -/-exhibited status epilepticus, which is in strong contrast to 7 out of 13 in the wildtype group (Fig. 3C) . The body weight of the mice did not significantly differ between the groups (Fig. 3D) . These data suggest that Prg1-haploinsufficiency significantly increases susceptibility for entry into status epilepticus, indicating that already a partial reduction of functional Prg1 at the synapse has important functional consequences for hippocampal network stability.
Double heterozygous Prg1/Scn1a-mutant mice show increased seizure susceptibility in adulthood.
We investigated the potential of Prg1 haploinsufficiency to modify the epileptic phenotype of heterozygous Scn1a wt/p.R1648H mice by crossing both lines to obtain double heterozygous Prg1 +/-|Scn1a wt/R1648H mice (Fig. 4) 
4D).
These data suggest that Prg1-haploinsufficiency significantly increases susceptibility for epileptic seizures in heterozygous Scn1a wt/p.R1648H mice.
ELECTROPHYSIOLOGY
The p.T300S mutation of Prg1 shows a loss-of-function effect in the mouse hippocampus.
To test the functional relevance of the human p.T299S missense mutation of PRG1 on the cellular level, we performed electrophysiological experiments on acute hippocampal brain slices ( Fig. 5) 
5D,E).
Next we set out to test whether in-utero electroporation of GFP/Prg1-constructs with the mutation corresponding to human p.T299S were able to rescue the electrophysiological effects seen in the Prg1 -/-neurons ( Fig. 5D,E In the hippocampus, the neurons of the CA3 region are known to be crucially involved in epileptogenesis (Zhang et al, 2012) . Hence we additionally performed whole cell patchclamp recordings from hippocampal CA3 pyramidal neurons (Fig. 5F ,G) and also found an mEPSC frequency that was significantly higher in Prg1 -/-mice as compared to wildtype lit-termates (2.47±0.32 Hz versus 5.15±0.64 Hz; unpaired two-tailed t-test: p=0.007). This confirms that loss of Prg1 function increased excitability in both CA1 and CA3 areas.
These results indicate that the construct corresponding to the human p.T299S mutation was unable to rescue Prg1 deficiency on the synaptic level. The persisting increase of excitatory glutamatergic transmission functionally confirms the loss-of-function of the human mutations.
DISCUSSION
In a previous study we show that homozygous Prg1-deficiency in mice resulted in neuronal hyperexcitability, early neuronal network synchronization, and seizures around postnatal days P18-21 (Vogt et al, 2017) . Heterozygous Prg1 +/-littermates had a normal EEG at resting state, but showed an increased susceptibility for epileptic seizures upon kainate stimulation.
This indicates a sub-threshold increase of neuronal excitability caused by PRG1 haploinsufficiency.
To follow-up on these observations, we searched for PRG1-mutations in human patients with epilepsy. The decision, which cohorts to screen, was guided by the mouse phenotype:
(i) Most homozygous Prg1 -/-mice convulse around postnatal days P18-21. This corresponds to a human age of 6-9 months, if referring to fundamental dynamics of brain growth, circuit organization and myelination (Levitt, 2003) . The Prg1 -/-mice who survived their spontaneous status epilepticus lived on normally after P22 (verified by video monitoring), when seizures spontaneously ceased (Trimbuch et al, 2009 ).
(ii) Prg1 is expressed in the mouse hippocampus during postnatal brain development (Bräuer et al, 2003; Unichenko et al, 2016) , and (iii)
the EEG of the Prg1 -/-animals showed prominent irregular high-amplitude, slow-frequency discharges, multifocal spikes, and absent topical organization reminiscent of hypsarrhythmia, a hallmark of West syndrome (Dulac, 2001) . We thus chose a cohort of 18 children with idiopathic West syndrome (infantile spasms).
In this cohort we found one child with a heterozygous PRG1-mutation resulting in the substitution of a serine for a threonine (p.T299S), which was absent in 400 Middle European control alleles, in 2,504 individuals of the 1000 genome project and present only once in heterozygous state in 122,802 individuals from the gnomAD server. Thr299 is located in the third extracellular domain in a motif that is highly evolutionary conserved in PRG1 and in other members of the LPP protein-family. Thr299 is located adjacent to Arg297, one of the critical amino acids for phospholipid interaction and de-phosphorylation of bioactive lipidphosphates (Zhang et al, 2000) . A similar mutation p.H253K, in the second extracellular domain that was previously introduced by in utero electroporation into embryonic mouse brains, disturbed the interaction between Prg1 with lysophosphatidic acid and to disrupt Prg1 function as shown by electrophysiological measurements (Trimbuch et al, 2009 ).
To establish whether the PRG1 p.T299S substitution affects protein function, we in-utero reexpressed the mouse homolog of the human mutation in neurons of Prg1 -/-mutants and investigated glutamatergic transmission in the hippocampus. Indeed, the altered p.T299S mutant Prg1 molecules were no longer able to control lipid signaling on the synaptic level in
Prg1
-/-neurons. This loss of function and subsequent dramatic increase in glutamatergic transmission would likely be a contributing factor to epileptogenesis, both in mice and in humans (Bianchi et al, 2012) .
Guided by our mouse data, where Prg1-haploinsufficiency significantly increases susceptibility for epileptic seizures, we assumed a modifying effect of the PRG1-variant since this variant was inherited from an unaffected parent. Our hypothesis was strengthened by the discovery of an additional p.N541S SCN1A variant in our patient. In our family the impact of the SCN1A variant alone seems to be insufficient to cause epileptic seizures as this variant had been inherited from the clinically unaffected mother and was also found in another healthy family member (Fig. 1A) . This mutation, which is not present in the SCN1A mutation databases or in the Human Genome Mutation Database (HGMD), was predicted to be diseasecausing by the MutationTaster2 software with a probability of P=0.999. It was found only once in the heterozygous state amongst 245,604 alleles from the gnomAD database, a large gene mutation databases of non-epileptic individuals. With respect to pathogenicity of a SCN1A variant we are aware that a number of SCN1A variants in the HGMD database would not be classifiable as "clearly pathogenic", and that, as recently pointed out, a significant fraction of patients identified with SCN1A mutations may actually not carry any SCN1A variant relevant for epileptogenesis (Lal et al, 2016) . We agree with these authors that the role of SCN1A missense variants in the pathogenesis of common epilepsies should not be overstated. However, we want to point out that the pathogenicity of a certain variant does not only depend on the functional alteration of the protein in isolation, but also on the functional network in which the protein operates. In some cases this network might compensate for a minor dysfunction (as in the mother and the uncle of our patient) and in other cases not (as in our patient with West syndrome).
A number of studies provide compelling evidence for the presence of genetic modifiers. Miller et al. demonstrated that disease severity in Scn1a mutant mice strongly depends on the genetic background of the respective mouse strain and identified several modifier loci (Miller et al, 2014) . Ohmori et al. reported that patients with SCN1A mutations plus certain CACNA1A variants had absence seizures more frequently than patients with SCN1A mutations alone and exhibited earlier seizure onset and prolonged seizure duration (Ohmori et al, 2013) . Singh et al. proposed SCN9A as a genetic modifier of Dravet syndrome, whereby SCN9A may exacerbate the impact of SCN1A mutations on neuronal excitability (Singh et al, 2009) . Despite these association studies, functional poof of a modifier for epilepsy in humans has not yet been provided. To study the effect of Prg1-mutations on a preexisting epileptic phenotype, we performed double mutant studies of Prg1 +/-mice carrying an epilepsycausing mutation in the Na v 1.1 sodium channel (Scn1a). This mutation has been previously identified in a large family exhibiting either febrile or afebrile generalized tonic-clonic or absence seizures (Escayg et al, 2000) . The SCNA1 mouse model recapitulates the human GEFS+ phenotype, showing spontaneous generalized seizures and a reduced threshold to thermally induced seizures even in a heterozygous state . Our epilepsy studies suggest a synergistic effect with respect to seizure susceptibility in Prg1-haploinsufficient mice additionally carrying an epilepsy-causing Scn1a mutation, a situation which in fact resembles the genetic background of our patient harboring two mutations in a heterozygous state.
Based on the functional data, we assume that a combined haploinsuffiency of PRG1 and SCN1A might be potent enough to evoke a transient severe seizure phenotype in our patient. The p.N541S variant is located in the large cytoplasmic loop between the first and second transmembrane segments of the SCN1A channel, a region known to be sometimes tolerant to substitutions, even if the substitution affects an evolutionarily conserved residue (Lal et al, 2016) . Hence this variant might only have a modest effect on channel function, illustrated by the fact the single SCN1A heterozygous individuals (Fig. 1A , II:3 and II:6) are seizure free, and its epileptogenic effect only becomes manifest in combination with the heterozygous PRG1 mutation.
In summary, our clinical and functional data indicate that PRG1-haploinsufficiency mediates an increase in excitability, sufficient to modify a pre-existing epileptic phenotype resulting in apparent aggravation and eventually seizures, but is not sufficient to cause seizures by itself.
We thus assume that heterozygous PRG1-mutations can act as a modifier of a pre-existing epileptic phenotype. Future studies will show, whether direct modulation of PRG1 or an indirect intervention via the blocking of LPA2-receptors might be a valuable pharmacological tool to treat juvenile forms of epilepsy. Using pharmacological intervention into phospholipid signaling, we were able to rescue the altered cortical somatosensory filter function in an animal model with monoallelic PRG1 deficiency pointing towards a new therapeutic ap-proach against epilepsy, e.g. via modulation of phospholipid signaling by pharmacological inhibition of the LPA-synthesizing molecule autotoxin (Vogt et al, 2016 ) by an orally bioavailable small molecule PF-8380 (Gierse et al, 2010) .
PATIENTS AND METHODS
Patient cohort
All patient-related studies were approved by the IRB of the Charité (EA1/215/08). All patients or caretakers provided written informed consent according to the Declaration of Helsinki. Guided by the timing of seizures and the EEG pattern of hypsarrhythmia, we selected a cohort of 18 patients suffering from idiopathic West syndrome with good outcome, who did not require antiepileptic drugs (AEDs) later in life. Brain malformations and metabolic disorders had been ruled out by appropriate imaging and metabolic studies.
Mutation screening in patients and control DNA samples
Genomic DNA was isolated from peripheral blood cells or from saliva by standard protocols.
All coding exons of PRG1 and 50 bp flanking intronic regions (GenBank NM_014839.4) were PCR-amplified and subjected to automatic sequencing with the BigDye® Terminator protocol (Applied Biosystems). Sequences were analyzed with the MutationSurveyor v3.10 (SoftGenetics) and the MutationTaster software (Schwarz et al, 2014) . PCR conditions and oligonucleotide primer sequences are available upon request. The presence of the c.896C>G
PRG1-mutation was verified in the patient and her family by restriction fragment length polymorphism (RFLP) analysis ( 
Whole Exome Sequencing
Exonic sequences were enriched from genomic DNA of the patient (Fig. 1A , III:2) and her parents (Fig. 1A , II:6 and II:7) using the SureSelect® V4 Human All Exon 51 Mb Kit (Agilent Technologies). Sequencing was done on a HiSeq®2500 machine (Illumina), which produced between 43-62 million 100 bp paired-end reads. The combined paired-end FASTQ files were aligned to the human GRCh37.p11 (hg19/Ensembl 72) genomic sequence using the BWA-MEM V.0.7.1 aligner (Li, 2013) . The raw alignments were fine-adjusted and called for deviations from the human reference sequence (GRCh37.p11) in all exonic ±50 bp flanking regions using the Genome Analysis Toolkit (GATK v3.8) software package McKenna et al, 2010) . The resulting variant (VCF) files comprised ≈60-80.000 variants and were sent to the MutationTaster2 Query Engine for assessment of the potential pathogenicity of all variants (Schwarz et al, 2014) . Subsequent downstream analysis of potentially pathogenic variants was restricted to the 350 known epilepsy genes (Supplementary table 01) .
De novo mutations in the patient were screened for by trio-WES. Subsequently we compared the patient's variant calling (VCF) file to those of her parents using the '--mendel' option of the VCFtools v0.1.14 software package to search for variants that were present in the patient, but not in her parents (Danecek et al, 2011) .
Animal studies
The animal studies were approved by the local animal welfare committee (LaGeSo T0100/03 & G0433/09, as well as G-12-096). We used male heterozygous Prg1 -/+ , homozygous Prg1 -/- (Trimbuch et al, 2009) , heterozygous Scn1a wt/p.R1648H (Hedrich et al, 2014; Martin et al, 2010) , and double heterozygous Prg1
wt/p.R1648H mutant mice on a C57BL/6J genetic background along with their wildtype littermates. In humans, the heterozygous p.R1648H mutation in SCN1A causes a GEFS+ phenotype (Escayg et al, 2000) . Mice were kept under SPFconditions with a 12 h dark/light cycle, had ad libitum access to food and water and were kept and euthanized in accordance with national regulations.
EEG recordings in freely moving animals using implanted epidural electrodes
Single tungsten wires (40 μm, California Fine Wire) were implanted into P18 pups under isoflurane anesthesia. Craniotomies were performed without damaging the underlying dura.
Electrodes were placed bilaterally at 2.0 mm posterior from bregma and 3.0 mm lateral from midline with a reference electrode above the cerebellum (Trimbuch et al, 2009) . Implanted electrodes were secured on the skull with dental acrylic. During recordings electrodes were connected to operational preamplifiers to eliminate cable movement artifacts. Electrophysiological signals were differentially amplified, band-pass filtered (1 Hz-10 kHz) and acquired continuously at 32 kHz (Neuralynx). Recordings were performed on freely moving animals at P19-P22 in 19 x 29 cm Plexiglas cages. EEG was obtained by low-pass filtering and downsampling of the wide-band signal to 1,250 Hz. Mice were monitored from different angles by two video cameras.
Seizure induction with kainic acid
Adult male 3-months-old wildtype (n=13), hetero-(n=24), and homozygous (n=14) Prg1- Epilepsy stages were evaluated by at least two independent investigators who were blinded for the genotypes. After the experiments animals tail cuts were genotyped and corresponding genotypes were assigned.
In-utero electroporation
The in-utero electroporation experiments in embryos from Prg1 +/-x Prg1 +/-matings were carried out in accordance with a protocol approved by the local animal welfare committee as described before (Prozorovski et al, 2008) . The wt and mutant Prg1-GFP plasmids (Trimbuch et al, 2009 ) were prepared at a concentration of 4 μg/μl using the EndoFree Plasmid Kit (Qiagen). We used mice from timed matings at E15-E16 (post coitum). After anesthesia with 10 mg/ml ketamine and 1 mg/ml xylazine, the uterine horns were exposed. The DNA solution (1.0-1.5 μl/embryo) was injected through the uterine wall into the lateral ventricle of two of the embryos by pulled glass capillaries (WPI). Electric pulses were delivered to embryos by holding the injected brain through the uterine wall with forceps-type electrodes (CUY650P5) connected to a square-pulse generator (CUY 21 Edit, Unique Medical Imada). Five 38 V pulses of 50 ms were applied at 950 ms intervals. The uterine horns were carefully replaced into the abdominal cavity before the muscle wall and skin were sutured. Animals were checked for the Prg1 -/-phenotype after birth and the efficacy of in-utero electroporation was assessed by visualization of the GFP-fluorescence signal, whose coding sequence was also present on the electroporated plasmid.
Electrophysiology P20-mice were anesthetized with isoflurane and decapitated. Brains were quickly removed and chilled in ice-cold, oxygenated, sucrose based artificial cerebrospinal fluid (sACSF) con- 7.4 at 300±10 mOsm. Normal ACSF was also used for recordings. All solutions were constantly equilibrated with carbogen (95% O 2 |5% CO 2 ).
Whole-cell voltage-clamp recordings were performed with an Axopatch 700B amplifier (Axon Instruments) and filtered at 2 kHz. Data were digitized (BNC-2090, National Instruments)
at 5-10 kHz, recorded and analyzed with custom-made software in IGOR Pro (WaveMetrics). 
Data analysis
Data was assessed for normal distribution and was analyzed accordingly. For group comparisons a nonparametric Kruskal-Wallis test was used. Non-parametric data were analyzed using the Mann-Whitney U-test. Post-hoc analysis was performed using the Dunn's multiple comparison test. Pearson's  2 was used for dichotomous (present/absent) values. Miniature
EPSCs were detected using a threshold algorithm generated in MatLab and/or Igor plug-in NeuroMatics and statistical significance was assessed with a Student's t-test.
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Also in hippocampal area CA3 the mEPSC frequency was significantly higher in Prg1 -/-mice as compared to wildtype mice. Representative traces of wildtype (black circle) and Prg1 -/-mice (white circle).
